



INFORMATION DISCLOSURE CITATION

Atty. Docket No. 06843.0052-00000	Appln. No. 10/748,112
Applicant Sanjay D. KHARE	
Filing Date December 29, 2003	Group: 1646

U.S. PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	N	2,512,572	06/20/1950	Smith et al.			
	N	3,773,919	11/20/1973	Boswell et al.			
	N	3,892,801	07/01/1975	Kazan			
	N	3,989,703	11/02/1976	Niculescu-Duvăz et al.			
	N	4,057,548	11/08/1977	Wiecko			
	N	4,067,867	01/10/1978	Wiecko			
	N	4,079,056	03/14/1978	Piper et al.			
	N	4,080,325	03/21/1978	Ellard			
	N	4,136,101	01/23/1979	Kazan			
	N	4,179,337	12/18/1979	Davis et al.			
	N	4,224,446	09/23/1980	Catalucci			
	N	4,289,872	09/15/1981	Denkewalter et al.			
	N	4,306,064	12/15/1981	Ellard et al.			
	N	4,374,987	02/22/1983	Singh et al.			
	N	4,421,913	12/20/1983	Ellard et al.			
	N	4,474,893	10/02/1984	Reading			
	N	4,619,794	10/28/1986	Hauser			
	N	4,699,880	10/13/1987	Goldstein			
	N	4,767,859	08/30/1988	Zimmermann			
	N	4,816,567	03/28/1989	Cabilly et al.			
	N	4,935,343	06/19/1990	Allison et al.			
	N	4,946,778	08/07/1990	Ladner et al.			
	N	4,970,154	11/13/1990	Chang			
	N	5,075,222	12/24/1991	Hannum et al.			
	N	5,106,627	04/21/1992	Aebischer et al.			
	N	5,136,021	08/04/1992	Dembinski et al.			

* Copies of U.S. Patent publications are not included.

Page 1 of 20 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

U.S. PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	N	5,151,510	09/29/1992	Stec et al.			
	N	5,180,812	01/19/1993	Dower et al.			
	N	5,229,490	07/20/1993	Tam			
	N	5,260,203	11/09/1993	Ladner et al.			
	N	5,319,071	06/07/1994	Dower et al.			
	N	5,344,915	09/06/1994	LeMaire et al.			
	N	5,359,032	10/25/1994	Dayer et al.			
	N	5,359,037	10/25/1994	Wallach et al.			
	N	5,399,346	03/21/1995	Anderson et al.			
	N	5,464,937	11/07/1995	Sims et al.			
	N	5,488,032	01/30/1996	Dower et al.			
	N	5,492,888	02/20/1996	Dower et al.			
	N	5,547,970	08/20/1996	Weithmann et al.			
	N	5,512,544	04/30/1996	Wallach et al.			
	N	5,593,875	01/14/1997	Wurm et al.			
	N	5,608,035	3/4/1997	Yanofsky et al.			
	N	5,633,145	05/27/1997	Feldmann et al.			
	N	5,641,673	06/24/1997	Haseloff et al.			
	N	5,672,344	09/30/1997	Kelley et al.			
	N	5,674,704	10/07/1997	Goodwin et al.			
	N	5,676,954	10/14/1997	Brigham			
	N	5,679,559	10/21/1997	Kim et al.			
	N	5,695,953	12/09/1997	Wallach et al.			
	N	5,747,444	05/05/1998	Haskill et al.			
	N	5,770,197	06/23/1998	Linsley et al.			
	N	5,773,253	06/30/1998	Linsley et al.			

‡ Copies of U.S. Patent publications are not included.

Page 2 of 20 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

U.S. PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	N	5,807,862	09/15/1998	Klein et al.			
	N	5,808,029	09/15/1998	Brockhaus et al.			
	N	5,811,261	09/22/1998	Wallach et al.			
	N	5,817,822	10/06/1998	Nantermet et al.			
	N	5,830,742	11/03/1998	Black et al.			
	N	5,834,435	11/10/1998	Slesarev			
	N	5,843,905	12/01/1998	Singh et al.			
	N	5,844,095	12/01/1998	Linsley et al.			
	N	5,851,556	12/22/1998	Breton et al.			
	N	5,851,795	12/22/1998	Linsley et al.			
	N	5,853,977	12/29/1998	Dalie et al.			
	N	5,854,003	12/29/1998	Rothe et al.			
	N	5,856,161	01/05/1999	Aggarwal et al.			
	N	5,859,207	01/12/1999	Johnson et al.			
	N	5,863,926	01/26/1999	Christensen et al.			
	N	5,866,576	02/02/1999	Underiner et al.			
	N	5,866,616	02/02/1999	Christensen et al.			
	N	5,869,315	02/09/1999	Talanian et al.			
	N	5,869,511	02/09/1999	Cohan et al.			
	N	5,869,660	02/09/1999	Adams et al.			
	N	5,869,677	02/09/1999	Christensen et al.			
	N	5,872,095	02/16/1999	Haskill et al.			
	N	5,872,146	02/16/1999	Baxter et al.			
	N	5,877,151	03/02/1999	Pereira			
	N	5,877,180	03/02/1999	Linden et al.			
	N	5,877,200	03/02/1999	Muller			

‡ Copies of U.S. Patent publications are not included.

Page 3 of 20 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

U.S. PATENT DOCUMENTS

Examiner Initial*	Copy Encl. [‡]	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	N	5,877,222	03/02/1999	McGrath			
	N	5,886,010	03/23/1999	Mori et al.			
	N	5,891,883	04/06/1999	Christensen et al.			
	N	5,912,324	06/15/1999	Okamura et al.			
	N	5,914,253	06/22/1999	Okamura et al.			
	N	5,929,117	07/27/1999	Muller et al.			
	N	5,932,208	08/03/1999	Chedid et al.			
	N	5,942,607	08/24/1999	Freeman et al.			
	N	5,948,638	09/07/1999	Lin et al.			
	N	5,952,320	09/14/1999	Davidsen et al.			
	N	5,955,435	09/21/1999	Baxter et al.			
	N	5,955,476	09/21/1999	Muller et al.			
	N	5,955,480	09/21/1999	Chang			
	N	5,962,481	10/05/1999	Levin et al.			
	N	5,965,564	10/12/1999	Bianco et al.			
	N	5,981,724	11/09/1999	Armitage et al.			
	N	5,990,119	11/23/1999	Christensen et al.			
	N	5,994,351	11/30/1999	Robinson et al.			
	N	6,025,376	02/15/2000	Laurent et al.			
	N	6,040,327	03/21/2000	De Nanteuil et al.			
	N	6,054,487	04/25/2000	Sekut et al.			
	N	6,060,283	05/09/2000	Okura et al.			
	N	6,090,382	07/18/2000	Salfeld et al.			
	N	6,258,562 B1	07/10/2001	Salfeld et al.			
	N	6,294,170 B1	09/25/2001	Boone et al.			
	N	6,344,457 B1	02/05/2002	Jeanpetit et al.			

† Copies of U.S. Patent publications are not included.

Page 4 of 20 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

U.S. PATENT DOCUMENTS

Examiner Initial*	Copy Encl. [‡]	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	N	6,344,464 B1	02/05/2002	Bourrie et al			
	N	6,355,779 B1	03/12/2002	Goodwin et al.			
	N	6,440,693 B1	08/27/2002	Hauptmann et al.			
	N	6,445,283 B1	09/03/2002	Pang et al.			
	N	6,492,370 B1	12/10/2002	Mita et al.			
	N	US 2003/0064480 A1		Lauffer et al.			04/30/2002
	N	US 2004/0080919 A1		Behammer			02/13/2003

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Copy Encl. [‡]	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	Y	DE 4219626 A1	12/23/1993	DE			Abstract only
	Y	AU-A-73636/91	10/03/1991	AU			
	Y	EP 0 036 676 B2	09/30/1981	EP			
	Y	EP 0 058 481 B2	08/25/1982	EP			
	Y	EP 0 133,988 A2	03/13/1985	EP			Abstract only
	Y	EP 0 143 949 B1	06/12/1985	EP			
	Y	EP 0 220 063 A2	04/29/1987	EP			
	Y	EP 0 267 611 B1	05/18/1988	EP			
	Y	EP 0 308 378 B1	03/22/1989	EP			
	Y	EP 0 364 778 B1	04/25/1990	EP			
	Y	EP 0 398 327 B1	11/22/1990	EP			
	Y	EP 0 412 486 B1	02/13/1991	EP			
	Y	EP 0 418 014 B1	03/20/1991	EP			
	Y	EP 0 422 339 B1	04/17/1991	EP			
	Y	EP 0 433 900 B1	06/26/1991	EP			

* Copies of U.S. Patent publications are not included.

Page 5 of 20 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Copy Encl. [‡]	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	Y	EP 0 445 228 B1	09/11/1991	EP			
	Y	EP 0 512 528 B1	11/11/1992	EP			
	Y	EP 0 526 905 A2	02/10/1993	EP			
	Y	EP 0 526 905 A3	02/10/1993	EP			
	Y	EP 0 534 978 B1	04/07/1993	EP			
	Y	EP 0 542 795 B1	05/26/1993	EP			
	Y	EP 0 550 376 A1	07/07/1993	EP			
	Y	EP 0 568 928 B1	11/10/1993	EP			
	Y	EP 0 614 984 B1	09/14/1994	EP			
	Y	EP 0 623 674 A1	11/09/1994	EP			
	Y	EP 0 648 783 B1	04/19/1995	EP			
	Y	EP 0 663 210 A2	07/19/1995	EP			
	Y	EP 0 663 210 A3	07/19/1995	EP			
	Y	EP 0 664 128 A1	07/26/1995	EP			
	Y	EP 0 712 931 B1	05/22/1996	EP			
	Y	EP 0 731 791 B1	09/18/1996	EP			
	Y	EP 0 741 707 B1	11/13/1996	EP			
	Y	EP 0 818 439 B1	01/14/1998	EP			
	Y	EP 0 850 952 A1	07/01/1998	EP			
	Y	EP 0 853 083 B1	07/15/1998	EP			
	Y	EP 0 864 585 A1	09/16/1998	EP			
	Y	EP 0 880 970 A1	12/02/1998	EP			
	Y	EP 0 882 714 A1	12/09/1998	EP			
	Y	EP 0 895 988 B1	02/10/1999	EP			
	Y	EP 0 939 121 B1	09/01/1999	EP			
	Y	EP 0 943 616 A1	09/22/1999	EP			

* Copies of U.S. Patent publications are not included.

Page 6 of 20 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	Y	EP 0 962 531 A2	12/08/1999	EP			
	Y	EP 0 962 531 A3	12/08/1999	EP			
	Y	EP 0 974 600 A2	01/26/2000	EP			
	Y	EP 0 974 600 A3	01/26/2000	EP			
	Y	EP 1 008 346 A1	06/14/2000	EP			
	Y	EP 1 110 969 A1	06/27/2001	EP			
	Y	FR 2706772	12/30/1994	FR			Abstract only
	Y	GB 2 218 101 A	11/08/1989	GB			
	Y	GB 2 246 569 A	02/05/1992	GB			
	Y	GB 2 326 881 A	01/06/1999	GB			
	Y	JP 10130149 A2	05/19/1998	JP			Abstract
	Y	JP 10147531 A2	06/02/1998	JP			Abstract
	Y	JP 10231285 A2	09/02/1998	JP			Abstract
	Y	JP 10259140 A2	09/29/1998	JP			Abstract
	Y	JP 10316570 A2	12/02/1998	JP			Abstract
	Y	JP 11001481 A	01/06/1999	JP			Abstract
	Y	WO 00/24782	05/04/2000	PCT			
	Y	WO 00/47740	08/17/2000	PCT			
	Y	WO 00/67034	11/09/2000	PCT			
	Y	WO 01/39722 A2	06/07/2001	PCT			
	Y	WO 01/85782 A2	11/15/2001	PCT			
	Y	WO 01/87977 A2	11/20/2001	PCT			
	Y	WO 01/92337 A2	12/06/2001	PCT			
	Y	WO 02/02638 A2	01/10/2002	PCT			
	Y	WO 02/002638 A3	01/10/2002	PCT			

‡ Copies of U.S. Patent publications are not included.

Page 7 of 20 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Copy Encl. [‡]	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	Y	WO 02/092620 A2	11/21/2002	PCT			
	Y	WO 88/01649	03/10/1988	PCT			
	Y	WO 90/05541	05/31/1990	PCT			
	Y	WO 90/06371	06/14/1990	PCT			Abstract only
	Y	WO 91/03553	03/21/1991	PCT			
	Y	WO 91/08285	06/13/1991	PCT			
	Y	WO 91/17184	11/14/1991	PCT			
	Y	WO 91/17249	11/14/1991	PCT			
	Y	WO 92/00092	01/09/1992	PCT			
	Y	WO 92/01002	01/23/1992	PCT			Abstract only
	Y	WO 92/13095	08/06/1992	PCT			
	Y	WO 92/16221	10/01/1992	PCT			
	Y	WO 93/00431	01/07/1993	PCT			
	Y	WO 93/07863	04/29/1993	PCT			
	Y	WO 93/08207	04/29/1993	PCT			
	Y	WO 93/15722	08/19/1993	PCT			
	Y	WO 93/19767	10/14/1993	PCT			
	Y	WO 93/19777	10/14/1993	PCT			
	Y	WO 93/21259	10/28/1993	PCT			
	Y	WO 93/21946	11/11/1993	PCT			
	Y	WO 93/24135	12/09/1993	PCT			
	Y	WO 94/02627	02/03/1994	PCT			Abstract only
	Y	WO 94/05691	03/17/1994	PCT			
	Y	WO 94/06457	03/31/1994	PCT			
	Y	WO 94/20069	09/15/1994	PCT			
	Y	WO 94/20517	09/15/1994	PCT			

[‡] Copies of U.S. Patent publications are not included.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Copy Encl. [‡]	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	Y	WO 94/21235	09/29/1994	PCT			
	Y	WO 94/26290	11/24/1994	PCT			
	Y	WO 94/28912	12/22/1994	PCT			
	Y	WO 95/01997	01/19/1995	PCT			
	Y	WO 95/04045	02/09/1995	PCT			
	Y	WO 95/09653	04/13/1995	PCT			
	Y	WO 95/34326	12/21/1995	PCT			
	Y	WO 96/09323	03/28/1996	PCT			
	Y	WO 96/11209	04/18/1996	PCT			
	Y	WO 96/12735	05/02/1996	PCT			
	Y	WO 96/20926	07/11/1996	PCT			
	Y	WO 96/22793	08/01/1996	PCT			
	Y	WO 96/23067	08/01/1996	PCT			
	Y	WO 96/25861	08/29/1996	PCT			
	Y	WO 96/28546	09/19/1996	PCT			
	Y	WO 96/32478	10/17/1996	PCT			
	Y	WO 96/33172	10/24/1996	PCT			
	Y	WO 96/35711	11/14/1996	PCT			
	Y	WO 96/38150	12/05/1996	PCT			
	Y	WO 96/40907	12/19/1996	PCT			
	Y	WO 96/40918	12/19/1996	PCT			
	Y	WO 96/40958	12/19/1996	PCT			
	Y	WO 97/08174	03/06/1997	PCT			
	Y	WO 97/11668	04/03/1997	PCT			
	Y	WO 97/12244	04/03/1997	PCT			
	Y	WO 97/12902	04/10/1997	PCT			

[‡] Copies of U.S. Patent publications are not included.

Page 9 of 20 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	Y	WO 97/18207	05/22/1997	PCT			
	Y	WO 97/23457	07/03/1997	PCT			
	Y	WO 97/24441	07/10/1997	PCT			
	Y	WO 97/28267	08/07/1997	PCT			
	Y	WO 97/28828	08/14/1997	PCT			
	Y	WO 97/34631	09/25/1997	PCT			
	Y	WO 97/37973	10/16/1997	PCT			
	Y	WO 97/37974	10/16/1997	PCT			
	Y	WO 97/43250	11/20/1997	PCT			
	Y	WO 97/47599	12/18/1997	PCT			
	Y	WO 98/01555	01/15/1998	PCT			
	Y	WO 98/17661	04/30/1998	PCT			
	Y	WO 98/21957	05/28/1998	PCT			
	Y	WO 98/24463	06/11/1998	PCT			
	Y	WO 98/30541	07/16/1998	PCT			
	Y	WO 98/32733	07/30/1998	PCT			
	Y	WO 98/33513	08/06/1998	PCT			
	Y	WO 98/38859	09/11/1998	PCT			
	Y	WO 98/39315	09/11/1998	PCT			
	Y	WO 98/39316	09/11/1998	PCT			
	Y	WO 98/39326	09/11/1998	PCT			
	Y	WO 98/39329	09/11/1998	PCT			
	Y	WO 98/39361	09/11/1998	PCT			
	Y	WO 98/41232	09/24/1998	PCT			
	Y	WO 98/42325	10/01/1998	PCT			
	Y	WO 98/42659	10/01/1998	PCT			

‡ Copies of U.S. Patent publications are not included.

Page 10 of 20 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Copy Encl. [‡]	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	Y	WO 98/43946	10/08/1998	PCT			
	Y	WO 98/43959	10/08/1998	PCT			
	Y	WO 98/44940	10/15/1998	PCT			
	Y	WO 98/45268	10/15/1998	PCT			
	Y	WO 98/47892	10/29/1998	PCT			
	Y	WO 98/51665	11/19/1998	PCT			
	Y	WO 98/52937	11/26/1998	PCT			
	Y	WO 98/52948	11/26/1998	PCT			
	Y	WO 98/53842	12/03/1998	PCT			
	Y	WO 98/56377	12/17/1998	PCT			
	Y	WO 98/56756	12/17/1998	PCT			
	Y	WO 98/56788	12/17/1998	PCT			
	Y	WO 98/57936	12/23/1998	PCT			
	Y	WO 98/58965	12/30/1998	PCT			
	Y	WO 99/00363	01/07/1999	PCT			
	Y	WO 99/00364	01/07/1999	PCT			
	Y	WO 99/01139	01/14/1999	PCT			
	Y	WO 99/01449	01/14/1999	PCT			
	Y	WO 99/02510	01/21/1999	PCT			
	Y	WO 99/03837	01/28/1999	PCT			
	Y	WO 99/04793	02/04/1999	PCT			Abstract only
	Y	WO 99/06041	02/11/1999	PCT			
	Y	WO 99/06042	02/11/1999	PCT			
	Y	WO 99/06410	02/11/1999	PCT			
	Y	WO 99/06426	02/11/1999	PCT			
	Y	WO 99/07679	02/18/1999	PCT			

† Copies of U.S. Patent publications are not included.

Page 11 of 20 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Copy Encl.‡	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	Y	WO 99/07704	02/18/1999	PCT			
	Y	WO 99/08688	02/25/1999	PCT			
	Y	WO 99/09022	02/25/1999	PCT			
	Y	WO 99/09063	02/25/1999	PCT			
	Y	WO 99/09965	03/04/1999	PCT			
	Y	WO 99/22760	05/14/1999	PCT			
	Y	WO 99/36415	07/22/1999	PCT			
	Y	WO 99/36426	07/22/1999	PCT			
	Y	WO 99/36541	07/22/1999	PCT			
	Y	WO 99/37625	07/29/1999	PCT			
	Y	WO 99/37772	07/29/1999	PCT			
	Y	WO 99/37773	07/29/1999	PCT			
	Y	WO 99/37818	07/29/1999	PCT			
	Y	WO 99/46248	09/16/1999	PCT			
	Y	WO 99/47154	09/23/1999	PCT			
	Y	WO 99/47545	09/23/1999	PCT			
	Y	WO 99/47672	09/23/1999	PCT			
	Y	WO 99/58674	11/18/1999	PCT			

Examiner Initial*	Copy Encl.‡	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Aguet et al., "Various human interferon α subclasses cross-react with common receptors: their binding affinities correlate with their specific biological activities," <i>Virology</i> , 132:211-216 (1984).
	Y	Akiba et al., "CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells," <i>J. Immunol.</i> , 162:7058-7066 (1999).
	Y	Al-Janadi et al., "Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases," <i>J. Clin. Immunology</i> , 13:58-67 (1993).

‡ Copies of U.S. Patent publications are not included.

Page 12 of 20 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

Examiner Initial*	Copy Encl. [‡]	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Aruffo et al., "Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system," <i>Proc. Natl. Acad. Sci. USA</i> , 84:8573-8579 (1987).
	Y	Auricchio et al., "Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column," <i>Human Gene Therapy</i> , 12:71-76 (2001).
	Y	Ausubel et al., eds., <i>Current Protocols in Molecular Biology</i> , Vols. 1, 2, 3 and 4, John Wiley & Sons, Inc. (1999) TABLE OF CONTENTS.
	Y	Bach et al., "The IFNy receptor: a paradigm for cytokine receptor signaling," <i>Annu. Rev. Immunol.</i> , 15:563-591 (1997).
	Y	Barrera et al., "Effects of antiheumatic agents on cytokines," <i>Seminars in Arthritis and Rheumatism</i> , 25:234-253 (1996).
	Y	Bischoff et al., "Preliminary model for methotrexate pharmacokinetics," <i>J. Pharm. Sci.</i> , 59(2) :149-154 (1970).
	Y	Boulianne et al., "Production of functional chimaeric mouse/human antibody," <i>Nature</i> , 312: 643-646 (1984).
	Y	Bowie et al., "A method to identify protein sequences that fold into a known three-dimensional structure," <i>Science</i> , 253:164-170 (1991).
	Y	Brenner et al., "Population statistics of protein structures: lessons from structural classifications," <i>Curr. Opn. Struct. Biol.</i> , 7:369-376 (1997).
	Y	Brodeur et al., "Mouse-human myeloma partners for the production of heterohybridomas," <i>Production of Heterohybridomas</i> , Ch. 4, pp. 51-63, Marcel Dekker, Inc., (1987).
	Y	Brody et al., "Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin-1 β to the interleukin-1 receptor on target cells," <i>Eur. J. Clin. Chem. Clin. Biochem.</i> , 31:667-674 (1993).
	Y	Brüggemann et al., "Designer mice: the production of human antibody repertoires in transgenic animals," <i>Year in Immunol.</i> , 7:33-40 (1993).
	Y	Brunet et al., "A new member of the immunoglobulin superfamily--CTLA-4," <i>Nature</i> , 328:267-270 (1987).
	Y	Buschle et al., "Interferon γ inhibits apoptotic cell death in B cell chronic lymphocytic leukemia," <i>J. Exp. Med.</i> , 177:213-218 (1993).
	Y	Cabilly et al., "Generation of antibody activity from immunoglobulin polypeptide chains produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 81:3273-3277 (1984).
	Y	Camerini et al., "The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family," <i>J. Immunol.</i> , 147:3165-3169 (1991).

† Copies of U.S. Patent publications are not included.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

Examiner Initial*	Copy Encl. [‡]	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Chothia et al., "Canonical structures for the hypervariable regions of immunoglobulins," <i>J. Mol. Biol.</i> , 196:901-917 (1987).
	Y	Chothia et al., "Conformations of immunoglobulin hypervariable regions," <i>Nature</i> , 342:877-883 (1989).
	Y	Chou et al., "Conformational parameters for amino acids in helical, β -Sheet, and random coil regions calculated from proteins," <i>Biochemistry</i> , 13:211-222 (1974).
	Y	Chou et al., "Prediction of protein confirmation," <i>Biochemistry</i> , 13:222-245 (1974).
	Y	Coligan et al., eds., <i>Current Protocols in Immunology</i> , Vols. 1, 2, and 3, John Wiley & Sons, Inc., (1997) TABLE OF CONTENTS.
	Y	Condit et al., "Studies on the folic acid vitamins," <i>Cancer</i> , 13:222-249 (1960).
	Y	Dinarello et al., "Overview of interleukin-18: more than an interferon- γ inducing factor," <i>J. Leukocyte Biol.</i> , 63:658-664 (1998).
	Y	Dürkop et al., "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease," <i>Cell</i> , 68:421-427 (1992).
	Y	Du Pasquier, "Evolution of the Immune System," <i>Fundamental Immunology</i> , Second Edition, Paul, ed., Raven Press, Ch. 7, p. 139-165 (1989).
	Y	Ellison et al., "The nucleotide sequence of a human immunoglobulin C γ 1 gene," <i>Nucl. Acids Res.</i> , 10:4071-9 (1982).
	Y	Eppstein et al., "Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor," <i>Proc. Natl. Acad. Sci. USA</i> , 82:3688-3692 (1985).
	Y	Evans et al., "Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists," <i>J. Med. Chem.</i> , 30:1229-1239 (1987).
	Y	Evans, "Methotrexate," <i>Applied Pharmacokinetics</i> , Evans, ed., Ch. 16 pp. 518-548 (1980).
	Y	Faggioni et al., "Leptin-deficient (<i>ob/ob</i>) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor α and IL-18," <i>Proc. Natl. Acad. Sci. USA</i> , 97:2367-2372 (2000).
	Y	Farrar et al., "The molecular cell biology of interferon- γ and its receptor," <i>Annu. Rev. Immunol.</i> , 11:571-611 (1993).
	Y	Fauchère, "Elements for the rational design of peptide drugs," <i>Adv. Drug Res.</i> , 15:29-69 (1986).
	Y	Freeman, "The fluorometric measurement of the absorption, distribution and excretion of single doses of 4-amino-10-methyl pteroylglutamic acid (amethopterin) in man," <i>J. Pharmacol. Exp. Ther.</i> , 122:154-162 (1958).

‡ Copies of U.S. Patent publications are not included.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

Examiner Initial*	Copy Encl. [‡]	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Freeman et al., "B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells," <i>J. Immunol.</i> , 143:2714-2722 (1989).
	Y	Freeman et al., "Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation," <i>Science</i> , 262:909-911 (1993).
	Y	Funauchi et al., "Serum level of interferon- γ in autoimmune disease," <i>Tohoku J. Exp. Med.</i> , 164:259-267 (1991).
	Y	Furst, "Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritis," <i>J. Rheumatol. Suppl.</i> , 12:11-14 (1985).
	Y	Gennaro, ed., <i>Remington's Pharmaceutical Sciences</i> , 18 th Edition, Mack Publishing Company (1990) TABLE OF CONTENTS.
	Y	Gómez-Foix et al., "Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism," <i>J. Biol. Chem.</i> 267:25129-25134 (1992).
	Y	Grawunder et al., "Interferon- γ arrests proliferation and causes apoptosis in stromal cell/interleukin-7-dependent normal murine pre-B cell lines and clones <i>in vitro</i> , but does not induce differentiation to surface immunoglobulin-positive B cells," <i>Eur. J. Immunol.</i> , 23:544-551 (1993).
	Y	Gribskov et al., "Profile analysis: detection of distantly related proteins," <i>Proc. Nat. Acad. Sci. USA</i> , 84:4355-4358 (1987).
	Y	Gribskov et al., "Profile analysis," <i>Meth. Enzym.</i> , 183:146-159 (1990).
	Y	Grosschedl et al., "Introduction of a μ immunoglobulin gene into the mouse germ line: specific expression in lymphoid cells and synthesis of functional antibody," <i>Cell</i> , 38: 647-658 (1984).
	Y	Hanahan, "Heritable formation of pancreatic β -cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes," <i>Nature</i> , 315:115-122 (1985).
	Y	Harlow et al., <i>Antibodies: A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press (1988) TABLE OF CONTENTS.
	Y	Haque et al., "Signal transduction in the interferon system," <i>Semin. Oncol.</i> , 25(suppl 1):14-22 (1998).
	Y	Henderson et al., "The metabolic fate of tritiated methotrexate," <i>Cancer Res.</i> , 25:1008-1017 (1965).
	Y	Herz et al., "Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice," <i>Proc. Natl. Acad. Sci.</i> 90:2812-2816 (1993).
	Y	Hoffmeister, "Methotrexate therapy in rheumatoid arthritis: 15 years experience," <i>Am. J. Med.</i> , 30:69-73 (1993).

† Copies of U.S. Patent publications are not included.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

Examiner Initial*	Copy Encl. [‡]	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Holm et al., "Protein folds and families: sequence and structure alignments," <i>Nucl. Acid. Res.</i> , 27:244-247 (1999).
	Y	Hoogenboom et al., "By-passing immunization: Human antibodies from synthetic repertoires of germline V _H gene segments rearranged <i>in vitro</i> ," <i>J. Mol. Biol.</i> , 227:381-388 (1992).
	Y	Isaacs et al., "Virus interference. I. The interferon," <i>Proc. R. Soc.</i> , 147:258-267 (1957).
	Y	Jaffe, "On the treatment of rheumatoid arthritis with M&Ms (Motrin & methotrexate)," <i>Arthritis and Rheumatism</i> , 31:299 (1988).
	Y	Jakobovits et al., "Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production," <i>Proc. Natl. Acad. Sci.</i> , 90:2551-2555 (1993).
	Y	Jakobovits et al., "Germ-line transmission and expression of a human-derived yeast artificial chromosome," <i>Nature</i> , 362:255-258 (1993).
	Y	Jolivet et al., "The pharmacology and clinical use of methotrexate," <i>N. Eng. J. Med.</i> , 309:1094-1104 (1983).
	Y	Jonasch et al. "Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities," <i>Oncologist</i> , 6:34-55 (2001).
	Y	Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <i>Nature</i> , 321:522-525 (1986).
	Y	Jones, "Progress in protein structure prediction," <i>Curr. Opin. Struct. Biol.</i> , 7:377-387 (1997).
	Y	Kabat et al., <i>Sequences of Proteins of Immunological Interest</i> , Fifth Edition, U.S. Department of Health and Human Services, (1991) TABLE OF CONTENTS.
	Y	Khare et al., "Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis," <i>J. Immunol.</i> , 155:3653-3659 (1995).
	Y	Khare et al., "Spontaneous inflammatory disease in HLA-B27 transgenic mice is independent of MHC class II molecules: a direct role for B27 heavy chains and not B27-derived peptides," <i>J. Immunol.</i> , 160:101-106 (1998).
	Y	Khare et al., "Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice," <i>Proc. Natl. Acad. Sci. USA</i> , 97:3370-3375 (2000).
*	Y	Kranz et al., "Restricted reassociation of heavy and light chains from hapten-specific monoclonal antibodies," <i>Proc. Natl. Acad. Sci. USA</i> , 78:5807-5811 (1981).
	Y	Langer et al., "Biocompatibility of polymeric delivery systems for macromolecules," <i>J. Biomed. Mater. Res.</i> , 15:267-277 (1981).
	Y	Langer, "Controlled release of macromolecules," <i>ChemTech</i> , 12:98-105 (1982).

‡ Copies of U.S. Patent publications are not included.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

Examiner Initial*	Copy Encl. [‡]	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Laughlin et al., "Cloning of infectious adeno-associated virus genomes in bacterial plasmids," <i>Gene</i> , 23:65-73 (1983).
	Y	LaPlanche et al., "Phosphorothioate-modified oligodeoxyribonucleotides. III. NMR and UV spectroscopic studies of the R _p -R _p , S _p -S _p and R _p -S _p duplexes, [d (GG _s AATTCC)] ₂ derived from diastereomeric O-ethyl phosphorothioates," <i>Nucl. Acids Res.</i> , 14:9081-9093 (1986).
	Y	Lesk, ed., <i>Computational Molecular Biology</i> , Oxford University Press (1988) TABLE OF CONTENTS.
	Y	Lewis et al., "Use of a novel mutagenesis strategy, optimized residue substitution, to decrease the off-rate of an anti-gp120 antibody," <i>Mol. Immunol.</i> , 32:1065-1072 (1995).
	Y	Lim et al., "Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products," <i>Ann. Rheum. Dis.</i> , 52:429-435 (1993).
	Y	Linsley et al., "Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation," <i>J Exp. Med.</i> , 173:721-730 (1991).
	Y	Liu et al., "Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells," <i>Proc. Natl. Acad. Sci. USA</i> , 84:3439-3443 (1987).
	Y	MacLennan et al., "Structure-function relationships in the Ca ²⁺ -binding and translocation domain of SERCA1: physiological correlates in Brody disease," <i>Acta Physiol. Scand. Suppl.</i> , 643:55-67 (1998).
	Y	Marks et al., "By-passing immunization: building high affinity human antibodies by chain shuffling," <i>Biotechnology</i> , 10:779-783 (1992).
	Y	Marks et al., "By-passing immunization: human antibodies from V-gene libraries displayed on phage," <i>J. Mol. Biol.</i> , 222:581-597 (1991).
	Y	Marston et al., "Solubilization of protein aggregates," <i>Meth. Enz.</i> , 182:264-276 (1990).
	Y	Masutani et al., "Predominance of Th1 immune response in diffuse proliferative lupus nephritis," <i>Arthritis & Rheumatism</i> , 44:2097-2106 (2001).
	Y	Merlin et al., " ¹²⁵ I-labelled human interferons alpha, beta and gamma: comparative receptor-binding data," <i>J. Gen. Virol.</i> , 66:1149-1152 (1985).
	Y	Miura et al., "Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40 ^{tax} ," <i>Mol. Cell Biol.</i> 11:1313:1325 (1991).
	Y	Morgan et al., "Folate status of rheumatoid arthritis patients receiving long-term, low dose methotrexate therapy," <i>Arthritis & Rheumatism</i> , 30:1348-1356 (1987).

* Copies of U.S. Patent publications are not included.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

Examiner Initial*	Copy Encl.‡	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Morrison et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," <i>Proc. Natl. Acad. Sci. USA</i> , 81:6851-6855 (1984).
	Y	Moult, "The current state of art in protein structure prediction," <i>Curr. Opin. Biotech.</i> , 7:422-427 (1996).
	Y	Müller, "Determination of affinity and specificity of anti-hapten antibodies by competitive radioimmunoassay," <i>Meth. Enzymol.</i> , 92:589-601 (1983).
	Y	Nabozny et al., "Identification of a cyanogen bromide fragment of porcine type II collagen capable of modulating collagen arthritis in B10.RIII(H-2 ^r) mice," <i>Autoimmunity</i> , 20:39-49 (1995).
	Y	Nakashima et al., "The combination of polymorphisms within interferon- γ receptor 1 and receptor 2 associated with the risk of systemic lupus erythematosus," <i>FEBS Lett.</i> , 453:187-190 (1999).
	Y	Narumi et al., "Serum levels of INF-inducible protein-10 relating to the activity of systemic lupus erythematosus," <i>Cytokine</i> , 12:1561-1565 (2000).
	Y	Neuberger et al., "Recombinant antibodies possessing novel effector functions," <i>Nature</i> , 312:604-608 (1984).
	Y	Neuberger et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function," <i>Nature</i> , 314:268-270 (1985).
	Y	Novelli et al., "Environmental signals influencing expression of the IFN- γ receptor on human T cells control whether IFN- γ promotes proliferation or apoptosis," <i>J. Immunol.</i> 152:496-504 (1994).
	Y	Perhala et al., "Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate," <i>Arthritis and Rheumatism</i> , 34:146-152 (1991).
	Y	Pestka, "The human interferon-alpha species and hybrid proteins," <i>Seminars Oncol.</i> , 24:S9-4-S9-17 (1997).
	Y	Pfeffer et al., "Biological properties of recombinant α -interferons: 40 th anniversary of the discovery of interferons," <i>Cancer Res.</i> , 58: 2489-2499 (1998).
	Y	Readhead et al., "Expression of a myelin basic protein gene in transgenic shiverer mice: correction of the dysmyelinating phenotype," <i>Cell</i> , 48:703-712 (1987).
	Y	Riechmann et al., "Reshaping human antibodies for therapy," <i>Nature</i> , 332:323-327 (1988).
	Y	Rodenhuis et al., "Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate," <i>Arthritis and Rheumatism</i> , 30:369-374 (1987).

‡ Copies of U.S. Patent publications are not included.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

Examiner Initial*	Copy Encl. [‡]	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Rojas et al., "Inhibition of apoptotic cell death in B-CLL by interferon gamma correlates with clinical stage," <i>Leukemia</i> , 10:1782-1788 (1996).
	Y	Rozzo et al., "Evidence for an interferon-inducible gene, <i>Ifi202</i> , in the susceptibility to systemic lupus," <i>Immunity</i> , 15:435-443 (2001).
	Y	Sambrook et al., <i>Molecular Cloning: A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press (1989) TABLE OF CONTENTS.
	Y	Samsonov et al., "Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus," <i>Lupus</i> , 4:29-32 (1995).
	Y	Sasaki et al., "Structure-mutation analysis of the ATPase site of <i>Dictyostelium discoideum</i> myosin II," <i>Adv. Biophys</i> , 35:1-24 (1998).
	Y	Schindler et al., "Transcriptional responses to polypeptide ligands: the JAK-STAT pathway," <i>Annu. Rev. Biochem</i> , 64:621-651 (1995).
	Y	Seeger et al., "Analogs of pteroylglutamic acid. III. 4-Amino derivatives," <i>J. Am. Chem. Soc.</i> , 71: 1753-1755 (1949).
	Y	Segal et al., "Methotrexate: mechanism of action in rheumatoid arthritis," <i>Seminars in Arthritis and Rheumatism</i> , 20:190-198 (1990).
	Y	Seitz et al., "Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells," <i>Br. J. Rheumatology</i> , 34:602-609 (1995).
	Y	Sidman et al., "Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid," <i>Biopolymers</i> , 22:547-556 (1983).
	Y	Smith et al., "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins," <i>Science</i> , 248:1019-1023 (1990).
	Y	Smith, ed., <i>Biocomputing: Informatics and Genome Projects</i> , Academic Press (1994) TABLE OF CONTENTS.
	Y	Sperling et al., "Acute and chronic suppression of leukotriene B ₄ synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate," <i>Arthritis and Rheumatism</i> , 35:376-384 (1992).
	Y	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas," <i>EMBO J.</i> , 8:1403-1410 (1989).
	Y	Ternowitz et al., "Methotrexate inhibits the human C5a-induced skin response in patients with psoriasis," <i>J. Inv. Derm.</i> , 89:192-196 (1987).
	Y	Theofilopoulos et al., "Murine models of systemic lupus erythematosus," <i>Adv. Immunol.</i> , 37:269-390 (1985).

‡ Copies of U.S. Patent publications are not included.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0052-00000	Appln. No.	10/748,112
Applicant	Sanjay D. KHARE		
Filing Date	December 29, 2003	Group:	1646

Examiner Initial*	Copy Encl. [‡]	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Y	Theofilopoulos et al., "The role of IFN- γ in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity," <i>Arthritis Res.</i> 3:136-141 (2001).
	Y	Uhlmann et al., "Antisense oligonucleotides: a new therapeutic principle," <i>Chemical Reviews</i> , 90: 543-584 (1990).
	Y	Van de Kerkhof et al., "Methotrexate inhibits the leukotriene B ₄ induced intraepidermal accumulation of polymorphonuclear leukocytes," <i>Brit. J. Derm.</i> , 113:251a-255a (1985).
	Y	Veber et al., "The design of metabolically-stable peptide analogs," <i>TINS</i> , 8: 392-396 (1985).
	Y	Verhoeven et al., "Reshaping human antibodies: grafting an antilysozyme activity," <i>Science</i> , 239: 1534-1536 (1988).
	Y	von Bülow et al., "NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily," <i>Science</i> , 278:138-140 (1997).
	Y	Vyse et al., "Genetic susceptibility to systemic lupus erythematosus," <i>Ann. Rev. Immunol.</i> , 16:261-292 (1998).
	Y	Wahl et al., "Improved radioimaging and tumor localization with monoclonal F(ab') ₂ ," <i>J. Nucl. Med.</i> , 24:316-325 (1983).
	Y	Weinblatt et al., "Efficacy of low-dose methotrexate in rheumatoid arthritis," <i>N. Eng. J. Med.</i> , 312:818-822 (1985).
	Y	Williams et al., "Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis," <i>Arthritis Rheum.</i> , 28:721-730 (1985).
	Y	Yokoyama et al., "Up-regulated MHC-class II expression and γ -IFN and soluble IL-2R in lupus nephritis," <i>Kidney Int.</i> , 42:755-763 (1992)
	Y	Zon et al., "Phosphorothioate oligonucleotides," <i>Oligonucleotides and Analogues: A Practical Approach</i> , Eckstein, ed., Oxford University Press, Ch. 4, p. 87-108 (1991).

Examiner	/Ilia Ouspenski/	Date Considered	02/06/2008
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce		

‡ Copies of U.S. Patent publications are not included.